Government Licenses Viral Peptide to Fight Liver Cancer
Published Date: 7/2/2026
Notice
Summary
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Potential New HCC Vaccine/Therapy
Researchers at the NCI report that a synthetic CE1 peptide can elicit T cell responses against HCC cells and could be developed as an immunotherapy or CE1-based HCC vaccine. The notice says such novel treatments could offer substantial public health benefits for people at risk of or living with hepatocellular carcinoma worldwide.
NIH Offers CE1 Peptide License
The National Cancer Institute (NCI) is offering a license and co-development opportunities for a viral peptide (CE1) intended for hepatocellular carcinoma (HCC) prevention and treatment (NIH Reference Number E-023-2024). The technology is at the Discovery stage and is being offered for commercial development; a related patent application (PCT/US2025/059785) was filed December 16, 2025.
New Diagnostic and Monitoring Uses
The NCI lists potential commercial applications including a predictive biomarker for HCC risk, a serological response test, patient stratification for CE1-based therapy, and tools to monitor vaccine efficacy. These applications could be developed and licensed for clinical use alongside CE1-based therapeutics.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
2026-13244 — The Federal Demonstration Partnership; Phase VIII Notice
The Federal Demonstration Partnership (FDP) is inviting colleges, universities, research groups, and hospitals that get federal research money to join its Phase VIII starting in 2027. This phase will keep testing new ways to make research funding and rules easier and faster. Applications are due by September 15, 2026, with the program running through the end of 2032.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13204 — Proposed Collection; 30-Day Comment Request; NIH Information Collection Forms to Support the Genetic Testing Registry (OD)
The NIH wants your thoughts on updating forms that help track genetic tests in their registry. If you’re involved in genetic testing or research, these changes could affect how you share info. You’ve got until July 30, 2026, to send in your comments—no cost, just your voice to help make things smoother and smarter!
2026-12843 — Government Owned Inventions Available for License: C8166-45 Cell Line
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!
Previous / Next Documents
Previous: 2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Next: 2026-13481 — Airworthiness Directives; Rolls-Royce Deutschland Ltd & Co KG Engines
If you own certain Rolls-Royce Deutschland Trent XWB engines, this new rule means you’ll need to check the main fuel hose more often for cracks, dents, or wear. Some engines require one-time inspections, while others need regular check-ups to keep flying safely. These changes start July 17, 2026, and could mean some repair costs if parts need replacing.